Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. Benjamin R, et al. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. Lancet Haematol. 2022. PMID: 36228643 Clinical Trial.
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
How J, Ren S, Lombardi-Story J, Bergeron M, Foster J, Amrein PC, Brunner AM, Fathi AT, Hock H, Khachatryan A, Kikuchi H, Ng MR, Moran J, Narayan R, Neuberg D, Ramos A, Som T, Vartanian M, Chen YB, Duda DG, Hobbs GS. How J, et al. Among authors: hock h. EJHaem. 2022 Mar 6;3(2):434-442. doi: 10.1002/jha2.408. eCollection 2022 May. EJHaem. 2022. PMID: 35846042 Free PMC article.
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
Amrein P, Ballen K, Stevenson K, Brunner A, Hobbs G, Hock H, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, McGreggor K, Macrea M, Burke M, Behnam T, Som T, Ramos A, Vartanian M, Lombardi Story J, Connolly C, Blonquist T, Neuberg D, Fathi A. Amrein P, et al. Among authors: hock h. Leuk Lymphoma. 2022 Jun;63(6):1428-1435. doi: 10.1080/10428194.2021.2018582. Epub 2022 Jan 25. Leuk Lymphoma. 2022. PMID: 35075985
The Second Oncogenic Hit Determines the Cell Fate of ETV6-RUNX1 Positive Leukemia.
Rodríguez-Hernández G, Casado-García A, Isidro-Hernández M, Picard D, Raboso-Gallego J, Alemán-Arteaga S, Orfao A, Blanco O, Riesco S, Prieto-Matos P, García Criado FJ, García Cenador MB, Hock H, Enver T, Sanchez-Garcia I, Vicente-Dueñas C. Rodríguez-Hernández G, et al. Among authors: hock h. Front Cell Dev Biol. 2021 Jul 15;9:704591. doi: 10.3389/fcell.2021.704591. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34336858 Free PMC article.
Culture in the spotlight-cultural adaptation and content validity of the integrated palliative care outcome scale for dementia: A cognitive interview study.
Hodiamont F, Hock H, Ellis-Smith C, Evans C, de Wolf-Linder S, Jünger S, Diehl-Schmid J, Burner-Fritsch I, Bausewein C. Hodiamont F, et al. Among authors: hock h. Palliat Med. 2021 May;35(5):962-971. doi: 10.1177/02692163211004403. Epub 2021 Apr 16. Palliat Med. 2021. PMID: 33863246 Free PMC article.
121 results